Tpl2 is a key mediator of arsenite-induced signal transduction

Cancer Res. 2009 Oct 15;69(20):8043-9. doi: 10.1158/0008-5472.CAN-09-2316. Epub 2009 Oct 6.

Abstract

Arsenite is a well-known human carcinogen that especially targets skin. The tumor progression locus 2 (Tpl2) gene encodes a serine/threonine protein kinase that is overexpressed in various cancer cells. However, the relevance of Tpl2 in arsenite-induced carcinogenesis and the underlying mechanisms remain to be explored. We show that arsenite increased Tpl2 kinase activity and its phosphorylation in mouse epidermal JB6 P+ cells in a dose- and time-dependent manner. Exposure to arsenite resulted in a marked induction of cyclooxygenase-2 (COX-2) and prostaglandin E(2) (PGE(2)), important mediators of inflammation and tumor promotion. Treatment with a Tpl2 kinase inhibitor or Tpl2 short hairpin RNA suppressed COX-2 expression and PGE(2) production induced by arsenite treatment, suggesting that Tpl2 is critical in arsenite-induced carcinogenesis. We also found that arsenite-induced phosphorylation of extracellular signal-regulated kinases (ERK) or c-Jun NH(2)-terminal kinases (JNK) was markedly suppressed by Tpl2 kinase inhibitor or Tpl2 short hairpin RNA. Inhibition of arsenite-induced ERK or JNK signaling using a pharmacologic inhibitor of ERK or JNK substantially blocked COX-2 expression. Furthermore, inhibition of Tpl2 reduced the arsenite-induced promoter activity of NF-kappaB and activator protein-1 (AP-1), indicating that NF-kappaB and AP-1 are downstream transducers of arsenite-triggered Tpl2. Our results show that Tpl2 plays a key role in arsenite-induced COX-2 expression and PGE(2) production and further elucidate the role of Tpl2 in arsenite signals that activate ERK/JNK and NF-kappaB/AP-1 in JB6 P+ cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arsenites / pharmacology*
  • Blotting, Western
  • Cells, Cultured
  • Cyclooxygenase 2 / metabolism
  • Epidermal Cells
  • Epidermis / drug effects*
  • Epidermis / metabolism
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Immunoprecipitation
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Luciferases / metabolism
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • MAP Kinase Kinase Kinases / genetics
  • MAP Kinase Kinase Kinases / metabolism*
  • Mice
  • NF-kappa B / metabolism
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism*
  • RNA, Small Interfering / pharmacology
  • Signal Transduction / drug effects*
  • Teratogens / pharmacology*
  • Transcription Factor AP-1 / metabolism

Substances

  • Arsenites
  • NF-kappa B
  • Proto-Oncogene Proteins
  • RNA, Small Interfering
  • Teratogens
  • Transcription Factor AP-1
  • Luciferases
  • Cyclooxygenase 2
  • Extracellular Signal-Regulated MAP Kinases
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinases
  • Map3k8 protein, mouse
  • arsenite